Timeline of cardiac dystrophy in 3-18-month-old mdx mice

Muscle and Nerve

Volumn 42, Issue 4, 2010, Pages 504-513

  Van Erp, Christel ^a,b   Loch, David ^a,b   Laws, Nicola ^a   Trebbin, Andrea ^a   Hoey, Andrew J ^a  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac fibrosis; Dystrophin; Mdx mouse heart; TGF

Indexed keywords

ADRENERGIC RECEPTOR; COLLAGEN; DYSTROPHIN; EVANS BLUE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; COLORING AGENT; SMAD2 PROTEIN; SMAD2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOMYOPATHY; CELL INFILTRATION; CELL MEMBRANE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FIBROSIS; HEART FUNCTION; HEART MUSCLE CELL; IN VIVO STUDY; INOTROPISM; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TEMPORAL LOBE; VASCULAR FRAGILITY; AGING; ANIMAL; C57BL MOUSE; CARDIOMYOPATHIES; COMPARATIVE STUDY; COMPLICATION; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; THORACIC AORTA; TIME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

AGING; ANIMALS; AORTA, THORACIC; CARDIOMYOPATHIES; COLORING AGENTS; EVANS BLUE; FIBROSIS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; PHOSPHORYLATION; RNA, MESSENGER; SMAD2 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77957660124     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21716     Document Type: Article

References (37)

1. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
2. McNally EM. Duchenne muscular dystrophy: how bad is the heart? Heart 2008;94:976-977.
3. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26:271-277.
4. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799-2804.
5. Williams IA, Allen DG. Intracellular calcium handling in ventricular myocytes from mdx mice. Am J Physiol Heart Circ Physiol 2007;292: H846-855.
6. Lu S, Hoey A. Changes in function of cardiac receptors mediating the effects of the autonomic nervous system in the muscular dystrophy (MDX) mouse. J Mol Cell Cardiol 2000;32:143-152. (Pubitemid 30064312)
7. Bostick B, Yue Y, Long C, Marschalk N, Fine DM, Chen J, et al. Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice. Mol Ther 2009;17:253-261.
8. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004;14:491-496.
9. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 2008;18:371-381.
10. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE, et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999;31:1857-1862. (Pubitemid 29458703)
11. Zhang W, ten Hove M, Schneider JE, Stuckey DJ, Sebag-Montefiore L, Bia BL, et al. Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: an MRI and MRS study. J Mol Cell Cardiol 2008;45:754-760.
12. Laws N, Hoey A. Progression of kyphosis in mdx mice. J Appl Physiol 2004;97:1970-1977.
13. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004;18:676-682. (Pubitemid 38451789)
14. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993;90:3710-3714.
15. Yue Y, Skimming JW, Liu M, Strawn T, Duan D. Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet 2004;13: 1669-1675.
16. Doherty KR, McNally EM. Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med 2003;9:327-330.
17. McNeil PL, Kirchhausen T. An emergency response team for membrane repair. Nat Rev Mol Cell Biol 2005;6:499-505. (Pubitemid 40780561)
18. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436:1025-1029. (Pubitemid 41191686)
19. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 2007;104: 264-269. (Pubitemid 46068020)
20. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord 2006;16:591-602. (Pubitemid 44374323)
21. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 2004;30:645-653. (Pubitemid 39447289)
22. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995;96:1137-1144.
23. Yamazaki M, Minota S, Sakurai H, Miyazono K, Yamada A, Kanazawa I, et al. Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. Am J Pathol 1994;144:221-226. (Pubitemid 24165943)
24. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006;34: 327-334. (Pubitemid 44300164)
25. Bostick B, Yue Y, Long C, Duan D. Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008;102:121-130.
26. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003;99:1-19.
27. Wilding JR, Schneider JE, Sang AE, Davies KE, Neubauer S, Clarke K. Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J 2005;19:79-81.
28. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005;288:R345-353.
29. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001;15:1655-1657.
30. Ishikawa K. Cardiac involvement in progressive muscular dystrophy of the Duchenne type. Jpn Heart J 1997;38:163-180.
31. Lanza GA, Dello Russo A, Giglio V, De Luca L, Messano L, Santini C, et al. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: relationship to myocardial and respiratory function. Am Heart J 2001;141:808-812. (Pubitemid 32378491)
32. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005;14:1921-1933. (Pubitemid 41418029)
33. Lu S, Hoey A. Age- and sex-associated changes in cardiac beta(1)- adrenoceptors from the muscular dystrophy (mdx) mouse. J Mol Cell Cardiol 2000;32:1661-1668.
34. Chu V, Otero JM, Lopez O, Sullivan MF, Morgan JP, Amende I, et al. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002;26: 513-519.
35. Anglister L, Etlin A, Finkel E, Durrant AR, Lev-Tov A. Cholinesterases in development and disease. Chem Biol Interact 2008;175: 92-100.
36. Carlson CG. Acetylcholine receptor and calcium leakage activity in nondystrophic and dystrophic myotubes (MDX). Muscle Nerve 1996; 19:1258-1267.
37. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004;24:429-434. (Pubitemid 38326134)